Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-20 12:32 pm Sale | 2025-08-19 | 13G | Y-mAbs Therapeutics, Inc. YMAB | ACORN BIOVENTURES, L.P. | 2,796,297 6.200% | -300,000 (-9.69%) | Filing History |
| 2025-08-15 4:28 pm Purchase | 2025-08-08 | 13G | Y-mAbs Therapeutics, Inc. YMAB | Glazer Capital, LLC | 2,654,700 5.840% | 2,654,700 (New Position) | Filing History |
| 2025-08-15 10:31 am Purchase | 2025-08-14 | 13G | Y-mAbs Therapeutics, Inc. YMAB | ACORN BIOVENTURES, L.P. | 3,096,297 7.000% | 769,769 (+33.09%) | Filing History |
| 2025-08-12 4:16 pm Purchase | 2025-08-05 | 13G | Y-mAbs Therapeutics, Inc. YMAB | Beryl Capital Management LLC | 4,087,091 9.000% | 4,087,091 (New Position) | Filing History |
| 2025-05-14 08:41 am Purchase | 2025-03-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | Caligan Partners LP | 2,342,609 5.200% | 2,342,609 (New Position) | Filing History |
| 2024-11-14 4:32 pm Purchase | 2024-09-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB | Paradigm BioCapital Advisors LP | 4,086,346 9.200% | 1,888,034 (+85.89%) | Filing History |
| 2024-11-12 6:00 pm Unchanged | 2024-09-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB | VANGUARD GROUP INC | 2,035,363 4.560% | 0 (Unchanged) | Filing History |
| 2024-11-04 2:16 pm Sale | 2024-09-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB | VANGUARD GROUP INC | 2,035,363 4.560% | -208,875 (-9.31%) | Filing History |
| 2024-04-08 5:09 pm Purchase | 2024-03-27 | 13G | Y-mAbs Therapeutics, Inc. YMAB | Paradigm BioCapital Advisors LP | 2,198,312 5.020% | 2,198,312 (New Position) | Filing History |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | WG Biotech ApS | 4,700,533 10.700% | 395,402 (+9.18%) | Filing History |
| 2024-02-13 5:17 pm Sale | 2023-12-29 | 13G | Y-mAbs Therapeutics, Inc. YMAB | VANGUARD GROUP INC | 2,244,238 5.140% | -14,016 (-0.62%) | Filing History |
| 2024-02-13 4:08 pm Sale | 2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | HBM Healthcare Investments (Cayman) Ltd. | 3,297,800 7.600% | -516,053 (-13.53%) | Filing History |
| 2024-02-06 3:59 pm Purchase | 2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | ACORN BIOVENTURES, L.P. | 2,761,825 6.300% | 2,761,825 (New Position) | Filing History |
| 2024-01-26 5:26 pm Purchase | 2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | BlackRock Inc. BLK | 2,917,080 6.700% | 338,304 (+13.12%) | Filing History |
| 2023-04-03 1:46 pm Purchase | 2023-03-15 | 13G | Y-mAbs Therapeutics, Inc. YMAB | ACORN BIOVENTURES, L.P. | 2,326,528 5.300% | 2,326,528 (New Position) | Filing History |
| 2023-02-14 4:03 pm Purchase | 2022-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | HBM Healthcare Investments (Cayman) Ltd. | 3,813,853 8.700% | 722,899 (+23.39%) | Filing History |
| 2023-02-14 1:50 pm Purchase | 2019-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | WG Biotech ApS | 4,305,131 9.800% | 4,305,131 (New Position) | Filing History |
| 2023-02-09 11:37 am Purchase | 2022-12-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB | VANGUARD GROUP INC | 2,258,254 5.170% | 2,258,254 (New Position) | Filing History |
| 2023-02-01 4:54 pm Sale | 2022-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | BlackRock Inc. BLK | 2,578,776 5.900% | -188,584 (-6.81%) | Filing History |
| 2022-04-11 08:51 am Sale | 2022-03-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | WELLINGTON MANAGEMENT GROUP LLP | 1,910,578 4.370% | -2,360,804 (-55.27%) | Filing History |